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An Option for the
High-Comorbidity Patient
With Mitral Regurgitation*
Zoltan G. Turi, MD,† Michael Rosenbloom, MD‡
Camden, New Jersey
The past 2 years have seen the culmination of a number of
important pivotal trials in percutaneous structural heart
disease intervention, including PARTNER A and B (Place-
ment of AoRTic TraNscathetER Valve Trial), EVEREST
II (Endovascular Valve Edge-in-Edge REpair STudy),
CLOSURE I, and PROTECT AF (Embolic Protection of
Patients in Atrial Fibrillation Trial), all attempting to
provide a high-level evidence base for selected patients with
aortic stenosis, mitral regurgitation (MR), patent foramen
ovale, and atrial fibrillation, respectively. In general, these
studies have yielded more nuanced results than their prede-
cessor registries and have dampened some of the enthusiasm
within the cardiology community for their major innova-
tions. The outcomes did not produce undisputed winners.
The EVEREST II (1), a randomized, controlled 2:1 com-
parison of the MitraClip device and mitral valve surgery, did
show a safety benefit (primarily transfusion rate) with less
See page 130
impressive early efficacy outcomes than surgery, but only
PARTNER B (2) has been deemed a clear “winner” by
most, comparing percutaneous aortic valve replacement
with conservative therapy resulted in better functional class
and lower mortality, albeit at a higher risk of stroke and
vascular complications. PARTNER B, like the EVEREST
High Risk Study (3) in this issue of the Journal, was an
investigation of patients judged too sick for surgery, but the
former was a randomized, controlled trial, whereas this
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problematic “comparator” group.
Among the therapeutic options for severe MR, medical
therapy is largely palliative, directed at controlling symp-
toms and manifestations of heart failure (4). Surgical inter-
vention is well tolerated in a population judged by surgeons
to be at acceptable risk; a number of registries and retro-
spective analyses have provided evidence consistent with the
superiority of surgery over medical therapy, of mitral valve
repair over replacement, and, where replacement has been
needed, of preservation of the subvalvular apparatus. How-
ever, in patients at high surgical risk due to multiple
comorbidities, the mandate for surgery is less compelling
(5). Moreover, until the EVEREST II trial randomized
patients to medical therapy versus percutaneous mitral valve
repair, the evidence base was remarkably lacking in high-
level clinical trials studying the outcomes of any intervention
for severe MR, surgical or percutaneous (6). Unfortunately,
the clinician with a high-risk patient still does not have a
solid evidence base with which to choose between medical
therapy and surgery, given substantial peri- and postopera-
tive morbidity and mortality (7) in this population.
In this context, the MitraClip procedure brings a poten-
tially important third approach for selected high-risk pa-
tients. Its predicate surgical method, the edge-to-edge
Alfieri repair (8) predominantly includes concomitant ring
placement. There is a relatively small evidence base exam-
ining isolated Alfieri repair without annuloplasty (9); the
omission of annuloplasty has been shown to create greater
mechanical stress on the edge-approximating stitch, the
likelihood of “accelerated failure of the repair,” and a higher
rate of need for reoperation (10). While the method and
extent of leaflet approximation with the percutaneous and
surgical techniques may not be identical, the lack of a
high-level evidence base comparing the isolated Alfieri
procedure with standard mitral valve repair limits our ability
to anticipate the effectiveness of the MitraClip approach.
With regard to the study by Whitlow et al. (3) in this
issue of the Journal, the authors address the outcomes in
a patient population that was judged too high risk for the
EVEREST II. We believe that this is a very important
study with substantial caveats. First, a major weakness is the
inadequacy of the “comparator” group. More than 50% were
screen failures and did not meet anatomic criteria, nonin-
vasive data were not read by the core laboratory, a number
did not have eligibility assessed by transesophageal echocar-
diography, patients were selected retrospectively and in-
cluded only a subset of those eligible, the sample size was
small, events were not adjudicated by the clinical events
committee, and no information is provided on patient man-
agement or any other outcomes parameter except survival.
Second, although the patients in both groups were high
risk, the nature of the high risk needs to be emphasized.
This was not a study of patients with dilated cardiomyop-
athy and poor left ventricular function: the mean ejection
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EVEREST II. Rather, this was a study of patients with
comorbidities. Compared with the EVEREST II popula-
tion, there was older age and greater presence of concomi-
tant coronary artery disease, chronic obstructive pulmonary
disease, diabetes, previous myocardial infarction, atrial fi-
brillation, previous cardiovascular surgery, previous percu-
aneous coronary intervention, and New York Heart
ssociation functional class III or IV. However, more
han one third of the patients did not meet the threshold
f a Society of Thoracic Surgeons score of 12, and their
isk assessment was augmented by a less rigorous “up
ssignment.” This does speak to known concerns about
he applicability of the Society of Thoracic Surgeons
coring system; PARTNER B added a similar set of high-
isk parameters to identify patients who were inoperable (2).
The outcomes are somewhat nuanced in this study as
ell. There was relatively high procedure-related mortality
or a percutaneous approach (8%). MR graded 2 or higher
as 46% through hospital discharge and 69% at 1 year. Both
re high; in EVEREST II, MR grade of 2 was 46% at
year (17% after surgery). Only 44% had a 2 grade
eduction in MR, whereas 19% had no change or a 1-grade
ncrease. A somewhat more optimistic perspective comes
rom looking at severe MR only; there was an 87% reduc-
ion to less severe over 12 months, overall left ventricular
imensions appeared to improve, and New York Heart
ssociation functional class decreased to I or II in 71% of
hose who were III or IV at baseline. However, interpreta-
ion of these follow-up data can be misleading; the reader
eeds to take into consideration the importance of the de
acto censoring of 31% of the patients (including the 24%
ho died before 1-year follow-up). Thus, comparisons, such
s shown in Figure 2 of Whitlow et al. (3), can result in the
eader overinterpreting the benefits of MitraClip in this
atient population. Unfortunately, only mortality data are
rovided for the comparator group, and we believe that its
eaknesses make the mortality benefit shown in Figure 3
ncertain.
What are the take-home lessons from the study by
hitlow et al. (3)? First, although a subset of patients who
ad MitraClip placement appeared to have encouraging
esults, we are concerned that this study not result in
enying the benefits of mitral valve repair to patients who in
act could undergo successful surgery. In our experience,
xcellent surgical results can be obtained in many patients
udged at high risk on the basis of cardiomyopathy rather
han comorbidities (11). Even with regard to the population
tudied in this high-risk registry, with high risk primarily
efined by comorbidities, we are concerned that patients
ave a full exploration of the risks and benefits of mitral
alve repair, and second the point made by Otto and Verrier
12) that patients being considered for our expanding
herapeutic options should be screened by a noninterven-
ional valve disease specialist, interventional cardiologist,
nd cardiac surgeon; we would add that the latter 2 shoulde experienced in structural heart disease interventions and
igh-risk mitral valve surgery, respectively.
Second, without PARTNER A– and B–like prospective,
andomized enrollment to MitraClip versus medical therapy
or patients who are high risk (A) and truly inoperable (B),
he benefits of MitraClip therapy in these patients will
emain uncertain. It will be important to consider what
onstitutes high risk and inoperable: multiple comorbidities
r dilated cardiomyopathy (or both). Among patients with a
ilated left ventricle and annulus, it will also be essential to
efine a subset of patients for whom the MitraClip will be
natomically suitable. Because of the heterogeneity of mitral
alve insufficiency (much more so than, for example, aortic
tenosis), this is a subset of patients with severe MR,
lthough this registry did include patients with both func-
ional and degenerative regurgitation. Many such patients
re currently offered only the limited benefits of conserva-
ive, primarily medical, therapy (13). These randomized
tudies should include a well-defined therapeutic strategy
nd detailed outcome analyses for both groups. We do
elieve that some of the concerns expressed regarding the
esults of EVEREST II would apply to a lesser degree in
hese trials. The long-term durability of MitraClip place-
ent may be less important in a population with comor-
idities that make 5-year survival less likely, even with
uccessful treatment of MR; in the inoperable groups, the
elatively high crossover rate to surgery in EVEREST II
ould presumably not occur. Therefore, any secondary
enefit seen in an intention-to-treat analysis would be less
ikely to confound a randomized trial.
Until then, we do not believe that the results of the
urrent registry can be extrapolated readily to routine
doption of the MitraClip for high-risk patients. However,
very cardiologist follows patients who are disabled with or
ying of this disease, with limited survival and without a
uitable alternative to medical therapy. The preliminary
esults of the EVEREST High Risk Registry suggest that
he percutaneous approach has a reasonable enough risk-to-
enefit ratio that it should continue to be available, albeit
nly if performed under investigational protocols by opera-
ors skilled at transseptal puncture and working in institu-
ions with extensive experience in percutaneous structural
eart interventions (14) as well as a proven track record with
itral valve repair in at least moderate-risk patients.
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